In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...
Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...
In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...
Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...
The clinical trials landscape will continue evolving toward greater decentralization, enhance patient-centricity, and increased global diversification. Industry projections suggest that by 2025, ...
In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...
When we think about where AI can help, it’s about reducing administrative burden. Tools like Smart Draft help streamline ...
In today’s ACT Brief, we look at efforts to address sex-based evidence gaps in Parkinson’s disease research, why ...
Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.
Unpack why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how ...
Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...
Mallon: The survey does highlight that principally prolonged contract and budget negotiations are probably the top barriers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback